Tesamorelin

Nature Reviews Drug Discovery

Volumn 10, Issue 2, 2011, Pages 95-96

  Grunfeld, Carl ^a   Dritselis, Argyris ^b   Kirkpatrick, Peter ^c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PLACEBO; RITONAVIR; TESAMORELIN; THYMIDINE DERIVATIVE;

DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; INSULIN RESISTANCE; LIPOATROPHY; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

ABDOMINAL FAT; ANIMALS; CLINICAL TRIALS AS TOPIC; GROWTH HORMONE-RELEASING HORMONE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS;

EID: 79551607900     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3362     Document Type: Short Survey

References (19)

1. Grunfeld, C. et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 11 8, E20-e28 (2008).
2. Grunfeld, C. et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 24, 1717-1726 (2010).
3. Crane, H. M. et al. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. HIV Med. 9, 780-786 (2008).
4. Koutkia, P. & Grinspoon, S. HIV-associated lipodystrophy: pathogenesis, Prognosis, Treatment, And controversies. Annu. Rev. Med. 55, 303-317 (2004).
5. Rietschel, P. et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metabol. 86, 504-510 (2001).
6. Lo, J. et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300, 509-519 (2008).
7. Stanley, T. L. et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab. 96, 150-158 (2011).
8. Koutkia, P. et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 292, 210-218 (2004).
9. Ferdinandi, E. S. et al. Non-clinical pharmacology and safety evaluation of TH9507, A human growth hormone-releasing factor analogue. Basic Clin. Pharmacol. Toxicol. 100, 49-58 (2007).
10. US Food and Drug Administration. FDA labelling information -Egrifta (tesamorelin for injection) FDA website [online], http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/022505s000lbl.pdf (2010).
11. Falutz, J. et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359-2370 (2007).
12. Falutz. J. et al. Long-term safety and effects of tesamorelin, A growth hormone-releasing factor analogue, In HIV patients with abdominal fat accumulation. AIDS 22, 1719-1728 (2008).
13. Falutz, J. et al. Effects of tesamorelin (TH9507), A growth hormone-releasing factor analog, In human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, Double-blind placebo-controlled phase 3 trials with safety extension data. J. Clin. Endocrinol. Metabol. 95, 4291-4304 (2010).
14. Després, J. P. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9, 452-459 (1993).
15. Thörne A. et al. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. Relat. Metab. Disord. 26, 193-199 (2002).
16. Klein, S. et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350, 2549-2557 (2004).
17. Silverberg, M. J. et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann. Intern. Med. 150, 301-313 (2009).
18. Loe, D. Research Update (Versant Partners, 6 Dec 2010).
19. Maruoka, N. Daily Letter (Canaccord Genuity, 6 Dec 2010).